Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

NCT03689595 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT03689595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03689595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Lead sponsor
Dana-Farber Cancer Institute
Phase
Observational
Overall status
Enrolling by invitation
Start date
October 31, 2018
Completion date
October 31, 2033
Enrollment
30,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma